Medical device with coating for capturing genetically-altered cells and methods for using same
AssigneeOrbusNeich Medical, Inc.
InventorsMichael Kutryk, Robert Cottone, Stephen Rowland, Michael Kuliszewski
Life of this patent
Estimating the term…
Loading patent…
AssigneeOrbusNeich Medical, Inc.
InventorsMichael Kutryk, Robert Cottone, Stephen Rowland, Michael Kuliszewski
Estimating the term…
Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and/or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.
1-34. (canceled)
An implantable stent comprising a stent structure with a surface coating of a biodegradable, bioactive polymer, wherein the polymer comprises at least one ligand covalently bound to the polymer wherein the ligand binds specifically to integrin receptors on progenitors of endothelial cells in circulating blood.
A kit comprising a bioactive implantable stent comprising a stent structure with a surface coating of a biodegradable, bioactive polymer and at least one ligand or first member of a specific binding pair is covalently bound to the biodegradable, biocompatible polymer, wherein the bioligand or the first member binds specifically to a target on therapeutic progenitor endothelial cells.
An implantable medical device having a biodegradable, bioactive polymer coated upon at least a portion of a surface thereof, wherein the polymer comprises at least one ligand covalently bound to the polymer, wherein the ligand specifically binds an integrin receptor on PECs found in peripheral blood.
Dependencies are inferred from the claim text.